|
| Status |
Public on Oct 01, 2024 |
| Title |
Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [4NQO_model] |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Regorafenib presented an antitumor activity in HNSCC mouse model and delayed the tumorigenesis of the 4NQO-indued oral mouse model. By tumor-infiltration lymphocytes isolation and RNA-seq analysis, the immunity-related function was activated by regorafenib. We approved that regorafenib can determine the macrophage polarization toward M1 inflammatory macrophages by suppressing the production of certain cytokines such as plasminogen activator inhibitor-1 (PAI-I) from tumor cells. Also, Regorafenib suppresses secretion of PAI-1 from ex vivo cultures of human HNSCC organoids.
|
| |
|
| Overall design |
We performed RNA-seq on tumors from HNSCC mouse model and 4NQO-indued oral mouse model with the treatment of vehicle control, regorafenib, anti-PD1, and regorafenib + anti-PD1
|
| |
|
| Contributor(s) |
Chen YH, Lee YM, Ou DL, Tang CT |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Nov 17, 2023 |
| Last update date |
Oct 01, 2024 |
| Contact name |
Chia-Lang Hsu |
| E-mail(s) |
chialanghsu@ntuh.gov.tw
|
| Organization name |
National Taiwan University Hospital
|
| Department |
Department of Medical Research
|
| Street address |
No. 7, Zhongshan S. Rd.
|
| City |
Taipei |
| ZIP/Postal code |
100 |
| Country |
Taiwan |
| |
|
| Platforms (1) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
| Samples (19)
|
| GSM7906491 |
4NQO-induced oral cancer models with treatment of anti-CD40 agonist (#1) |
| GSM7906492 |
4NQO-induced oral cancer models with treatment of anti-CD40 agonist (#2) |
| GSM7906493 |
4NQO-induced oral cancer models with treatment of anti-CD40 agonist (#3) |
| GSM7906494 |
4NQO-induced oral cancer models with treatment of vehicle control (#1) |
| GSM7906495 |
4NQO-induced oral cancer models with treatment of vehicle control (#2) |
| GSM7906496 |
4NQO-induced oral cancer models with treatment of vehicle control (#3) |
| GSM7906497 |
4NQO-induced oral cancer models with treatment of vehicle control (#4) |
| GSM7906498 |
4NQO-induced oral cancer models with treatment of anti-PD1 (#1) |
| GSM7906499 |
4NQO-induced oral cancer models with treatment of anti-PD1 (#2) |
| GSM7906500 |
4NQO-induced oral cancer models with treatment of anti-PD1 (#3) |
| GSM7906501 |
4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#1) |
| GSM7906502 |
4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#2) |
| GSM7906503 |
4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#3) |
| GSM7906504 |
4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#4) |
| GSM7906505 |
4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#5) |
| GSM7906506 |
4NQO-induced oral cancer models with treatment of regorafenib (#1) |
| GSM7906507 |
4NQO-induced oral cancer models with treatment of regorafenib (#2) |
| GSM7906508 |
4NQO-induced oral cancer models with treatment of regorafenib (#3) |
| GSM7906509 |
4NQO-induced oral cancer models with treatment of regorafenib (#4) |
|
| This SubSeries is part of SuperSeries: |
| GSE248155 |
Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma |
|
| Relations |
| BioProject |
PRJNA1041838 |
Less...
More...